Early or late guided missile in the treatment of Crohn's disease?
R Caprilli1, E Angelucci, A Cocco
1Gastroenterology Unit, Department of Clinical Sciences, University of Rome La Sapienza, Policlinico Umberto I, Italy. renzo.caprilli@uniroma1.it
Abstract:
Over the last few years, much light has been shed on the pathogenesis of Crohn's disease. Further knowledge in this field has provided a firm basis not only in the understanding of current treatment but also for the development of new therapeutic strategies. Aim of these new agents is primarily to selectively interact with the key processes of intestinal inflammation. At present, only anti-tumour necrosis factor-alpha antibodies namely infliximab, is licensed for clinical practice but it is feasible to foresee that, in the near future, a larger range of these agents will become available. Herein, the most promising biological agents in the treatment of Crohn's disease are outlined, which patients would benefit from these agents and when they should be administered. Attention is focused on the early (top-down) or late (step-up) use of biological agents, which for their very targeted mechanism of action may be compared to guided missiles. As yet, early use of biological agents remains to be supported by convincing evidence, nevertheless it may be advocated as first-line therapy for newly diagnosed severe Crohn's disease patients, both adults and children.
Insights
New biological agents offer targeted treatments for Crohn's disease, selectively acting on intestinal inflammation. Early use as first-line therapy may benefit newly diagnosed severe Crohn's disease patients.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Significant advancements in understanding Crohn's disease pathogenesis.
- Current treatments are limited, with only anti-tumour necrosis factor-alpha antibodies (infliximab) licensed.
- New therapeutic strategies are being developed to target key inflammatory processes.
Purpose of the Study:
- To outline promising biological agents for Crohn's disease treatment.
- To identify patient populations who would benefit from these agents.
- To discuss optimal timing for the administration of biological therapies.
Main Methods:
- Review of current literature on biological agents for Crohn's disease.
- Analysis of selective anti-inflammatory mechanisms.
- Discussion of early (top-down) versus late (step-up) treatment approaches.
Main Results:
- Several promising biological agents are emerging beyond infliximab.
- These agents offer targeted action against intestinal inflammation.
- The optimal timing for initiating biological therapy is under investigation.
Conclusions:
- Biological agents represent a significant advancement in Crohn's disease management.
- Early intervention with biological agents may be beneficial for severe, newly diagnosed patients.
- Further evidence is needed to fully support early (top-down) use as first-line therapy.
More Related Videos
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD: